[Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Giant cell tumour of bone (GCTB) is an aggressive bone tumour causing bone destruction. GCTB requires surgical treatment, and severe cases have a high risk of functional morbidity. GCTB consists of receptor activator of nuclear factor kappa-B (RANK)-positive osteoclast-like giant cells. The formation and activity of these cells are mediated by the interaction with RANK ligand (RANKL) released from neoplastic stromal cells. Denosumab is a human monoclonal antibody which inhibits RANKL and impairs the growth of the GCTB. Several studies have described the ability of denosumab to downgrade the extent of surgical treatment and improve the functional outcome.
anlyso@rm.dk.
Anna Lynge
AL
Sørensen
Rehne Lessmann
RL
Hansen
Peter Holmberg
PH
Jørgensen
D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D000069448:Denosumab / Q000494:pharmacology / Q000627:therapeutic use*; D018212:Giant Cell Tumor of Bone / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D011859:Radiography; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab